Description: Frequency Therapeutics is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Frequency’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapeutics. The company’s lead product candidate, FX-322, is in clinical development and is designed to regenerate auditory hair cells to restore hearing function in patients with sensorineural hearing loss, the most common form of hearing loss. The company is also evaluating its PCA approach in additional diseases, including multiple sclerosis.
Home Page: www.frequencytx.com
FREQ Technical Analysis
75 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
781 315 4600
Officers
| Name | Title |
|---|---|
| Mr. David L. Lucchino | Co-Founder, Pres, CEO & Director |
| Dr. Carl P. LeBel Ph.D. | Chief Devel. Officer |
| Dr. Quentin McCubbin Ph.D. | Chief Manufacturing Officer |
| Dr. Christopher R. Loose Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. James P. Abely | Associate Gen. Counsel & Sec. |
| Ms. Wendy S. Arnold | Chief People Officer |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer |
| Dr. John L. LaMattina Ph.D. | Sr. Advisor & Member of PCA Regenerative Medicine Advisory Board |
| Dr. William W. Chin M.D. | Sr. VP of Translational Medicine |
| Mr. Jason Glashow | Sr. VP of Corp. Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9077 |
| Price-to-Sales TTM: | 7.5026 |
| IPO Date: | 2019-10-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 72 |